DTL
CLDX icon

Dynamic Technology Lab’s Celldex Therapeutics CLDX Stock Holding History

Dynamic Technology Lab’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-5,637
Closed -$242K – 1043
2017
Q3 		$242K Buy
+5,637
New +$211K 0.04% 829
2014
Q4 		– Sell
-720
Closed -$140K – 679
2014
Q3 		$140K Buy
+720
New +$157K 0.07% 546

Other funds holding CLDX

CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KE
KLP Enterprises Branford, Connecticut $1.97M AUM
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Dynamic Technology Lab's CLDX Position: Q4 2017 in Review

Dynamic Technology Lab sold out of Celldex Therapeutics (CLDX) in Q4 2017, closing a stake of 5,637 shares — an estimated $242K sold.

Dynamic Technology Lab first reported a position in CLDX in Q3 2014 and held it in 2 quarters. The position peaked at $242K in Q3 2017. 135 funds tracked by Wall St. Rank hold CLDX as of Q4 2017.

  • Dynamic Technology Lab reported no remaining Celldex Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Dynamic Technology Lab sold 5,637 Celldex Therapeutics shares in Q4 2017, an estimated $242K.
  • Dynamic Technology Lab first reported a position in Celldex Therapeutics in Q3 2014 and held it in 2 quarters.
  • Dynamic Technology Lab's Celldex Therapeutics position peaked at $242K in Q3 2017.
  • 135 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2017.

Based on Dynamic Technology Lab's 13F filing for Q4 2017, filed 9 Feb 2018.